Compare VCEL & MMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VCEL | MMS |
|---|---|---|
| Founded | 1989 | 1975 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 4.7B |
| IPO Year | 1997 | 1997 |
| Metric | VCEL | MMS |
|---|---|---|
| Price | $40.38 | $91.41 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 1 |
| Target Price | $57.50 | ★ $90.00 |
| AVG Volume (30 Days) | 591.3K | ★ 631.8K |
| Earning Date | 02-26-2026 | 02-05-2026 |
| Dividend Yield | N/A | ★ 1.35% |
| EPS Growth | ★ 236.54 | 10.42 |
| EPS | 0.25 | ★ 5.51 |
| Revenue | $258,716,999.00 | ★ $5,431,276,000.00 |
| Revenue This Year | $17.86 | $1.71 |
| Revenue Next Year | $18.55 | $4.98 |
| P/E Ratio | $159.52 | ★ $16.17 |
| Revenue Growth | ★ 14.05 | 2.36 |
| 52 Week Low | $29.24 | $63.77 |
| 52 Week High | $63.00 | $92.50 |
| Indicator | VCEL | MMS |
|---|---|---|
| Relative Strength Index (RSI) | 63.46 | 67.02 |
| Support Level | $35.33 | $85.78 |
| Resistance Level | $38.15 | $91.09 |
| Average True Range (ATR) | 1.42 | 2.00 |
| MACD | 0.32 | 0.31 |
| Stochastic Oscillator | 84.25 | 82.77 |
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Maximus Inc designs, develops, and delivers programs enabling people to access vital government services. It translates health and human services public policy into operating models that achieve outcomes for governments at scale. The company covers a broad array of services, including the operation of large health insurance eligibility and enrollment programs; clinical services, including assessments, appeals, and independent medical reviews; and technology services. The company operates through the following segments: U.S. Federal Services, U.S. Services, and Outside the U.S. A majority of its revenue is derived from the U.S. Federal Services segment, which engages with various U.S. federal government agencies to deliver clinical services, maintenance services, and technology solutions.